loading
Collegium Pharmaceutical Inc stock is traded at $30.64, with a volume of 101.29K. It is down -0.92% in the last 24 hours and up +5.24% over the past month. Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
See More
Previous Close:
$30.95
Open:
$30.82
24h Volume:
101.29K
Relative Volume:
0.24
Market Cap:
$998.14M
Revenue:
$566.77M
Net Income/Loss:
$48.16M
P/E Ratio:
25.75
EPS:
1.19
Net Cash Flow:
$274.29M
1W Performance:
-4.53%
1M Performance:
+5.24%
6M Performance:
-11.50%
1Y Performance:
-7.66%
1-Day Range:
Value
$30.55
$31.09
1-Week Range:
Value
$30.23
$32.03
52-Week Range:
Value
$28.39
$42.29

Collegium Pharmaceutical Inc Stock (COLL) Company Profile

Name
Name
Collegium Pharmaceutical Inc
Name
Phone
781-713-3699
Name
Address
100 TECHNOLOGY CENTER DRIVE, STOUGHTON, MA
Name
Employee
197
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
COLL's Discussions on Twitter

Compare COLL with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - Specialty & Generic icon
COLL
Collegium Pharmaceutical Inc
30.64 998.14M 566.77M 48.16M 274.29M 1.19
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
171.44 78.56B 9.15B 2.43B 2.31B 5.32
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
13.54 43.15B 30.25B 1.37B 5.08B 0.4257
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.545 43.00B 14.26B 1.55B 0 0.3383
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.63 19.59B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
NBIX
Neurocrine Biosciences Inc
124.02 15.24B 2.24B 385.90M 440.10M 3.73

Collegium Pharmaceutical Inc Stock (COLL) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-10-25 Upgrade Needham Hold → Buy
Jul-30-24 Upgrade H.C. Wainwright Neutral → Buy
Jun-07-24 Upgrade Jefferies Hold → Buy
May-10-24 Downgrade Needham Buy → Hold
May-10-24 Downgrade Piper Sandler Overweight → Neutral
Jan-04-24 Downgrade Jefferies Buy → Hold
Aug-25-23 Reiterated Needham Buy
May-02-23 Resumed Jefferies Buy
Aug-08-22 Downgrade H.C. Wainwright Buy → Neutral
Feb-15-22 Upgrade Cantor Fitzgerald Neutral → Overweight
Aug-06-21 Downgrade Cantor Fitzgerald Overweight → Neutral
Jan-11-21 Reiterated H.C. Wainwright Buy
Jul-14-20 Initiated BWS Financial Sell
May-27-20 Initiated Guggenheim Neutral
Feb-19-20 Resumed Jefferies Buy
Oct-30-19 Reiterated Needham Buy
May-03-19 Resumed H.C. Wainwright Buy
Apr-12-19 Resumed Janney Buy
Mar-20-19 Initiated SunTrust Hold
Jan-16-19 Reiterated Needham Buy
Mar-08-18 Reiterated H.C. Wainwright Buy
Feb-07-18 Reiterated Needham Buy
Dec-05-17 Reiterated Needham Buy
Sep-11-17 Initiated H.C. Wainwright Buy
May-11-17 Reiterated Needham Buy
Sep-13-16 Initiated Gabelli & Co Buy
Jun-01-15 Initiated Jefferies Buy
Jun-01-15 Initiated Needham Buy
Jun-01-15 Initiated Piper Jaffray Overweight
View All

Collegium Pharmaceutical Inc Stock (COLL) Latest News

pulisher
04:22 AM

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Stock Position Raised by Caprock Group LLC - Defense World

04:22 AM
pulisher
Feb 06, 2025

Piper Sandler Has Lowered Expectations for Collegium Pharmaceutical (NASDAQ:COLL) Stock Price - Defense World

Feb 06, 2025
pulisher
Feb 06, 2025

Collegium Pharmaceutical (NASDAQ:COLL) Price Target Cut to $36.00 by Analysts at Piper Sandler - MarketBeat

Feb 06, 2025
pulisher
Feb 06, 2025

Collegium Pharmaceutical expands board, appoints new director - MSN

Feb 06, 2025
pulisher
Feb 05, 2025

Collegium Pharmaceutical, Inc. Appoints Nancy S. Lurker to Its Board of Directors -February 05, 2025 at 08:00 am EST - Marketscreener.com

Feb 05, 2025
pulisher
Feb 05, 2025

Collegium Pharmaceutical expands board with new director - MSN

Feb 05, 2025
pulisher
Feb 05, 2025

Collegium Pharmaceutical expands board, appoints new director By Investing.com - Investing.com South Africa

Feb 05, 2025
pulisher
Feb 05, 2025

Collegium Pharmaceutical Expands Board with Nancy Lurker - TipRanks

Feb 05, 2025
pulisher
Feb 05, 2025

Collegium Appoints Nancy S. Lurker to its Board of Directors - GlobeNewswire

Feb 05, 2025
pulisher
Feb 05, 2025

Pharma Veteran Nancy Lurker Joins Collegium Board: Ex-Novartis CMO Brings M&A Expertise - StockTitan

Feb 05, 2025
pulisher
Feb 05, 2025

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Sold by Robeco Institutional Asset Management B.V. - MarketBeat

Feb 05, 2025
pulisher
Feb 04, 2025

Collegium Pharmaceutical Insiders Sell US$2.3m Of Stock, Possibly Signalling Caution - Simply Wall St

Feb 04, 2025
pulisher
Feb 04, 2025

SG Americas Securities LLC Sells 4,586 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Defense World

Feb 04, 2025
pulisher
Feb 01, 2025

Collegium Pharmaceutical, Inc. announces an Equity Buyback for $100 million worth of its shares. - Marketscreener.com

Feb 01, 2025
pulisher
Jan 31, 2025

Pacer Advisors Inc. Trims Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - MarketBeat

Jan 31, 2025
pulisher
Jan 31, 2025

Nisa Investment Advisors LLC Has $71,000 Stock Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Defense World

Jan 31, 2025
pulisher
Jan 29, 2025

Amid more drug-price scrutiny, biopharma companies largely keep their January hikes in check - FiercePharma

Jan 29, 2025
pulisher
Jan 21, 2025

Assenagon Asset Management S.A. Trims Stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - MarketBeat

Jan 21, 2025
pulisher
Jan 21, 2025

Assenagon Asset Management S.A. Has $4.31 Million Stock Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Defense World

Jan 21, 2025
pulisher
Jan 20, 2025

Ritholtz Wealth Management Has $968,000 Stock Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - MarketBeat

Jan 20, 2025
pulisher
Jan 20, 2025

Needham Upgrades Collegium Pharmaceutical (COLL) - MSN

Jan 20, 2025
pulisher
Jan 17, 2025

Burney Co. Sells 38,157 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - MarketBeat

Jan 17, 2025
pulisher
Jan 16, 2025

Brokerages Set Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Target Price at $43.80 - Defense World

Jan 16, 2025
pulisher
Jan 15, 2025

Collegium pharmaceutical EVP Shirley Kuhlmann sells $908,627 in stock By Investing.com - Investing.com Australia

Jan 15, 2025
pulisher
Jan 14, 2025

Insider Selling: Collegium Pharmaceutical, Inc. (NASDAQ:COLL) EVP Sells 27,500 Shares of Stock - MarketBeat

Jan 14, 2025
pulisher
Jan 14, 2025

Despite the downward trend in earnings at Collegium Pharmaceutical (NASDAQ:COLL) the stock swells 18%, bringing three-year gains to 82% - Simply Wall St

Jan 14, 2025
pulisher
Jan 14, 2025

Collegium pharmaceutical EVP Shirley Kuhlmann sells $908,627 in stock - Investing.com

Jan 14, 2025
pulisher
Jan 13, 2025

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat

Jan 13, 2025
pulisher
Jan 13, 2025

JPMorgan Chase & Co. Has $10.71 Million Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Defense World

Jan 13, 2025
pulisher
Jan 13, 2025

JPMorgan Chase & Co. Grows Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - MarketBeat

Jan 13, 2025
pulisher
Jan 12, 2025

Collegium Pharmaceutical (NASDAQ:COLL) Raised to “Buy” at Needham & Company LLC - Defense World

Jan 12, 2025
pulisher
Jan 12, 2025

Collegium Pharmaceutical (NASDAQ:COLL) Earns Buy Rating from HC Wainwright - Defense World

Jan 12, 2025
pulisher
Jan 11, 2025

Collegium Pharma spikes after 2025 outlook - MSN

Jan 11, 2025
pulisher
Jan 10, 2025

Collegium Pharmaceutical (NASDAQ:COLL) Stock Rating Upgraded by Needham & Company LLC - MarketBeat

Jan 10, 2025
pulisher
Jan 09, 2025

Collegium Pharmaceutical Unveils 2025 Financial Projections - Yahoo Finance

Jan 09, 2025
pulisher
Jan 08, 2025

COLLCollegium Pharmaceutical, Inc. Latest Stock News & Market Updates - StockTitan

Jan 08, 2025
pulisher
Jan 08, 2025

Collegium Pharmaceutical (NASDAQ:COLL) Trading 2.8% HigherShould You Buy? - MarketBeat

Jan 08, 2025
pulisher
Jan 08, 2025

Collegium Pharma stock spikes on 2025 outlook (COLL:NASDAQ) - Seeking Alpha

Jan 08, 2025
pulisher
Jan 08, 2025

Collegium Pharmaceutical, Inc. Provides Earnings Guidance for the Year 2025 -January 08, 2025 at 08:00 am EST - Marketscreener.com

Jan 08, 2025
pulisher
Jan 08, 2025

Collegium Provides 2025 Financial Guidance and Business Update - GlobeNewswire

Jan 08, 2025
pulisher
Jan 08, 2025

Collegium Pharmaceutical Projects Record $750M Revenue in 2025, ADHD Drug Leads Growth - StockTitan

Jan 08, 2025
pulisher
Jan 07, 2025

Collegium Pharmaceutical (NASDAQ:COLL) Sets New 12-Month LowHere's What Happened - MarketBeat

Jan 07, 2025
pulisher
Jan 02, 2025

Collegium stock hits 52-week low at $28.46 amid market challenges - Investing.com Australia

Jan 02, 2025
pulisher
Dec 31, 2024

Collegium Pharmaceutical to Report Q3 Earnings: What's in the Cards? - MSN

Dec 31, 2024
pulisher
Dec 30, 2024

Collegium Pharmaceutical (NASDAQ:COLL) Hits New 12-Month LowWhat's Next? - MarketBeat

Dec 30, 2024
pulisher
Dec 29, 2024

Franklin Resources Inc. Has $1.16 Million Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Defense World

Dec 29, 2024
pulisher
Dec 27, 2024

Geode Capital Management LLC Has $29.97 Million Stock Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Defense World

Dec 27, 2024

Collegium Pharmaceutical Inc Stock (COLL) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Collegium Pharmaceutical Inc Stock (COLL) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Kuhlmann Shirley R.
EVP and General Counsel
Jan 10 '25
Sale
33.04
27,500
908,628
119,184
$31.70
price up icon 1.05%
$11.61
price down icon 2.88%
$89.17
price down icon 1.96%
$10.78
price down icon 1.15%
$127.12
price up icon 0.00%
$124.17
price down icon 17.55%
Cap:     |  Volume (24h):